Launch week offerEnds in00h00m00s

annual Promonthly Pro

Aleksandra Konieczna

Assistant Professor

Maria Sklodowska-Curie National Research Institute of Oncology

Poland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Poland

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Collaborators (3)

Małgorzata Pieniążek

Wroclaw Medical University

POLAND

View details

Zuzana Bielcikova

Charles University

CZECH REPUBLIC

View details

Renata Pacholczak-Madej

National Cancer Institute

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aleksandra Konieczna

Research Interests

Make your next move.

Explore related searches

Articles (20)

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study

Revisiting neoadjuvant strategies in HER2-positive early breast cancer: are chemotherapy-sparing ADC-based approaches the next frontier?

Baseline inflammatory indexes and prognosis for progression-free survival in first-line pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer: A Polish multicenter cohort study.

Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.

Real-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: A multicenter cohort from Poland, the Czech Republic, and Slovakia.

Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.

Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.

Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.

Impact of Germline <i>BRCA1/2</i> Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland, the Czech Republic and Slovakia

Abstract PS1-05-12: Primary G-CSF Prophylaxis in Sacituzumab Govitecan-Treated mTNBC: Real-World Evidence from a Multinational Cohort

Abstract PS1-08-01: Safety of Combining Radiotherapy With Sacituzumab Govitecan in Patients With Advanced Triple-Negative Breast Cancer: An International Multicenter Cohort Study

Abstract PS2-04-15: Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort

Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data

Abstract PS5-03-04: Timing of final oncologist visit and systemic treatment use near the end of life in advanced triple-negative breast cancer: a multinational cohort study

Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

Collaborators (3)

Małgorzata Pieniążek

Zuzana Bielcikova

Renata Pacholczak-Madej

Make your next move.

Aleksandra Konieczna

Research Interests

Make your next move.

Explore related searches

Articles (20)

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study

Revisiting neoadjuvant strategies in HER2-positive early breast cancer: are chemotherapy-sparing ADC-based approaches the next frontier?

Baseline inflammatory indexes and prognosis for progression-free survival in first-line pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer: A Polish multicenter cohort study.

Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.

Real-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: A multicenter cohort from Poland, the Czech Republic, and Slovakia.

Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.

Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.

Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.

Impact of Germline &lt;i&gt;BRCA1/2&lt;/i&gt; Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland, the Czech Republic and Slovakia

Abstract PS1-05-12: Primary G-CSF Prophylaxis in Sacituzumab Govitecan-Treated mTNBC: Real-World Evidence from a Multinational Cohort

Abstract PS1-08-01: Safety of Combining Radiotherapy With Sacituzumab Govitecan in Patients With Advanced Triple-Negative Breast Cancer: An International Multicenter Cohort Study

Abstract PS2-04-15: Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort

Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data

Abstract PS5-03-04: Timing of final oncologist visit and systemic treatment use near the end of life in advanced triple-negative breast cancer: a multinational cohort study

Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

Collaborators (3)

Małgorzata Pieniążek

Zuzana Bielcikova

Renata Pacholczak-Madej

Make your next move.

Impact of Germline <i>BRCA1/2</i> Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland, the Czech Republic and Slovakia